Jeanette M. Bjorkquist net worth and biography

Jeanette Bjorkquist Biography and Net Worth

Insider of Assembly Biosciences

Jeanette Bjorkquist is the Insider of Assembly Biosciences. They are 39 years old.

What is Jeanette M. Bjorkquist's net worth?: The estimated net worth of Jeanette M. Bjorkquist is at least $139.90 thousand as of March 31st, 2025. Bjorkquist owns 4,617 shares of Assembly Biosciences stock worth more than $139,895 as of May 14th. This net worth approximation does not reflect any other investments that Bjorkquist may own. Learn More about Jeanette M. Bjorkquist's net worth.
How do I contact Jeanette M. Bjorkquist?: The corporate mailing address for Bjorkquist and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on Jeanette M. Bjorkquist's contact information.
Has Jeanette M. Bjorkquist been buying or selling shares of Assembly Biosciences?: Jeanette M. Bjorkquist has not been actively trading shares of Assembly Biosciences within the last three months. Most recently, Jeanette M. Bjorkquist sold 180 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $9.85, for a transaction totalling $1,773.00. Following the completion of the sale, the insider now directly owns 4,617 shares of the company's stock, valued at $45,477.45. Learn More on Jeanette M. Bjorkquist's trading history.
Who are Assembly Biosciences' active insiders?: Assembly Biosciences' insider roster includes Jeanette Bjorkquist (Insider), William Delaney (Insider), Michael Houghton (Director), John McHutchison (CEO), Jason Okazaki (CEO), Timothy Springer (Director), and Nicole White (Insider). Learn More on Assembly Biosciences' active insiders.

Jeanette M. Bjorkquist Insider Trading History at Assembly Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/31/2025	Sell	180	$9.85	$1,773.00	4,617
5/23/2024	Sell	24	$14.93	$358.32	3,142
4/1/2024	Sell	114	$13.07	$1,489.98	3,166
7/24/2023	Sell	70	$12.84	$898.80	2,224
5/23/2023	Sell	22	$12.48	$274.56	2,294
3/30/2023	Sell	64	$9.84	$629.76	1,983

Jeanette M. Bjorkquist Buying and Selling Activity at Assembly Biosciences

Assembly Biosciences Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Today's Range

Now: $30.30

$30.04

$32.46

50 Day Range

MA: $28.78

$26.33

$31.72

2 Week Range

Now: $30.30

$12.19

$39.71

Volume

69,452 shs

Average Volume

105,538 shs

Market Capitalization

$481.47 million

P/E Ratio

N/A

Dividend Yield